The EMPT‐ANGINA randomized trial evaluated the effect of empagliflozin, a sodium–glucose cotransporter 2 (SGLT2) inhibitor, on angina symptoms and exercise capacity in patients with both type 2 diabetes mellitus (T2DM) and refractory angina (RA). Here, SLC5A2 is linked to type 2 diabetes mellitus.